Imugene is partnering with another research phase company. It looks like a good match - combining OnCARlytics with a next generation CAR-T. Just don't expect immediate $$ to flow from this - it's a longer term project with no revenue in the short term.
It continues Imugene's strategic path of broadening their IP and product base - with a partner who will probably do a lot of the work - further derisking Imugene. This is just one direction for OnCARlytics - and it could be very successful. I expect Imugene will end up with several partners for further development of OnCARlytics.
Another good move on the Biotech chessboard. Plenty more to come, and the money will follow in due course.
Cheers
Dave
Ann: Research partnership with Celularity for solid tumors, page-14
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |